In today’s recent session, 720,945 shares of the KemPharm, Inc.(NASDAQ:KMPH) have been traded, and its beta is 3.36. Most recently the company’s share price was $10.03, and it changed around $0.23 or 0.02% from the last close, which brings the market valuation of the company to $283.74 Million. KMPH at last check was trading at a discount to its 52-week high of $22.08, offering almost -120.14% off that amount. The share price’s 52-week low was $1.94, which indicates that the recent value has risen by an impressive 80.66% since then. We note from KemPharm, Inc.’s average daily trading volume that its 10-day average is 1.12 Million shares, with the 3-month average coming to 4.41 Million.
KemPharm, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 2 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 1 recommended KMPH as a Hold, whereas 1 deemed it a Buy, and no one rated it as Underweight. KemPharm, Inc. is expected to report earnings per share of $1.62 for the current quarter.
KemPharm, Inc. (NASDAQ:KMPH): Trading Information Today
Instantly KMPH has been showing a green trend so far today with a performance of 2.35% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $10.28 on Wednesday, Apr 07 increased the stock’s daily price by 0.58%. The company’s shares are currently down -0.09% year-to-date, but still up 0.0679 over the last five days. On the other hand, KemPharm, Inc. (NASDAQ:KMPH) is 0.02% up in the 30-day period. We can see from the shorts that 2.61 Million shares have been sold at a short interest cover period of 0.59 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bears needing to increase their stock price by 99.4% from its current value. Analyst projections state that KMPH is forecast to be at a low of $12 and a high of $28. In order for the stock price to hit the forecast high, the stock would need to surge +179.16% from its current level, while the stock would need to crash 19.64% from its current level to reach the projected low.
KemPharm, Inc. (KMPH) projections and forecasts
KemPharm, Inc. share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +11.01 percent over the past six months and at a -147% annual growth rate that is well below the industry average of 17.2%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +184.4% in revenue this quarter, and will report a decline of -131.2% in the next quarter. The year-over-year growth rate is expected to be 312.4%, up from the previous year.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 51.4%. KemPharm, Inc. earnings are expected to increase by 75.8% in 2021, but the outlook is negative 0% per year for the next five years.
KemPharm, Inc. (NASDAQ:KMPH)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 3.14% of KemPharm, Inc. shares, and 7.82% of them are in the hands of institutional investors. The stock currently has a share float of 8.07%. KemPharm, Inc. stock is held by 6 institutions, with Ifp Advisors, Inc being the largest institutional investor. By Dec 30, 2020, it held 0.03% of the shares, which is about 1.25 Thousand shares worth $14Thousand.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.